ClinicalTrials.gg
WithdrawnNCT02560363Updated Jan 11, 2016

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

A Phase 1 interventional study of AZD9977 immediate release (IR) oral suspension and AZD9977 extended release (ER) capsules [fast] in Pharmacokinetics, Healthy Male Subjects and Safety, sponsored by AstraZeneca. Withdrawn at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Why this study was withdrawn
Has been terminated before FSFV.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is an open-label, randomized, cross over single oral dose study to compare the pharmacokinetics of different formulations of AZD9977 in Part A and the influence of food in Part B in healthy male subjects

Read the detailed description

This is an open-label, randomized, cross over single oral dose study to compare the pharmacokinetics of three different extended-release formulations and an immediate-release formulation (reference) of AZD9977 in Part A and the influence of food in Part B in healthy male subjects

02

Conditions studied

  • Pharmacokinetics
  • Healthy Male Subjects
  • Safety
  • Food Effect

Keywords

  • AZD9977
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Food effect
  • AZD9977 capsules
  • AZD9977 suspension
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.
  • Male subjects have to comply with the restrictions for sexual activity provided to them.
  • Have a (BMI) between 18 and 32 kg/m2, inclusive, and weigh at least 50 kg.
  • Subject judged likely to complete and agree to eat a specified high-fat, high-calorie standardized FDA breakfast.
  • Able to understand, read and speak the English language.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  • History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results, as judged by the investigator.
  • Any positive result on screening for serum surface antigen (HBsAg), antibody and (HIV) antibody.
  • Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

    • Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg
    • Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg
    • Pulse \< 45 or > 90 bpm
  • Any clinically important abnormalities in rhythm, conduction or morphology of the (ECG) at screening or pre-dose, as considered by the investigator.
  • Prolonged > 450 ms or family history of long QT syndrome.
  • PR (PQ) interval shortening \< 120 ms (PR > 110 ms but \< 120 ms is acceptable if there is no evidence of ventricular pre-excitation).
  • PR (PQ) interval prolongation > 240 ms; intermittent second (history of Wenckebach block while asleep is not exclusive) or third degree atrioventricular (AV) block or AV dissociation.
  • Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB) or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but \< 115 ms are acceptable if there is no evidence of ventricular hypertrophy or pre-excitation.
  • Serum potassium higher than 5.0 mmol/L at screening or admission to the study center (Day -1).
  • Known or suspected history of drug abuse, as judged by the investigator.
  • Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.
  • History of alcohol abuse or excessive intake of alcohol as judged by the investigator.
  • Positive screen for drugs of abuse, alcohol or cotinine at screening or admission to the study center.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.
  • Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.
  • Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to first dose of AZD9977.
  • Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to 1st dosing in Part A, or longer if the medication has a long half-life.
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.
  • Subjects who have previously received AZD9977
  • Involvement of any AstraZeneca, PAREXEL, or study site employee or their close relatives.
  • Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
  • Subjects who are vegans, vegetarians or have medical dietary restrictions.
  • Subjects who cannot communicate reliably with the investigator.
  • Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1

    Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food

    Drug: AZD9977 immediate release (IR) oral suspension · Drug: AZD9977 extended release (ER) capsules [fast] · Drug: AZD9977 extended release (ER) capsules [intermediate] · Drug: AZD9977 extended release (ER) capsules [slow]

  • Experimental
    Treatment sequence 2

    Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food

    Drug: AZD9977 immediate release (IR) oral suspension · Drug: AZD9977 extended release (ER) capsules [fast] · Drug: AZD9977 extended release (ER) capsules [intermediate] · Drug: AZD9977 extended release (ER) capsules [slow]

  • Experimental
    Treatment sequence 3

    Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food

    Drug: AZD9977 immediate release (IR) oral suspension · Drug: AZD9977 extended release (ER) capsules [fast] · Drug: AZD9977 extended release (ER) capsules [intermediate] · Drug: AZD9977 extended release (ER) capsules [slow]

  • Experimental
    Treatment sequence 4

    Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food

    Drug: AZD9977 immediate release (IR) oral suspension · Drug: AZD9977 extended release (ER) capsules [fast] · Drug: AZD9977 extended release (ER) capsules [intermediate] · Drug: AZD9977 extended release (ER) capsules [slow]

Interventions

06

What researchers measure

Primary outcomes

  1. Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (AUC)

    Relative bioavailability (Frel \[AUC\]) by assessement of the ratio of AUC (Area under plasma concentration-time curve from time zero extrapolated to infinity) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  2. Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (AUC0-t)

    Relative bioavailability (Frel \[AUC0-t\]) by assessement of the ratio of AUC (Area under the plasma concentration-curve from time zero to time of last quantifiable concentration) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  3. Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (AUC0-24)

    Relative bioavailability (Frel \[AUC0-24\]) by assessement of the ratio of AUC (Area under the plasma concentration-time curve from time zero to 24 hours post-dose) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  4. Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (Cmax)

    Relative bioavailability (Frel \[Cmax\]) by assessement of the ratio of AUC (Observed maximum plasma concentration) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  5. Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel (AUC)

    Relative bioavailability (Frel \[AUC\]) by assessement of the ratio of AUC (Area under plasma concentration-time curve from time zero extrapolated to infinity) after dosing of an extended-release formulation under fed and fasting conditions

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  6. Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel(AUC0-t)

    Relative bioavailability (Frel \[AUC0-t\]) by assessement of the ratio of AUC (Area under the plasma concentration-curve from time zero to time of last quantifiable concentration) after dosing of an extended-release formulation under fed and fasting conditions

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  7. Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel(AUC0-24)

    Relative bioavailability (Frel \[AUC0-24\]) by assessement of the ratio of AUC (Area under the plasma concentration-time curve from time zero to 24 hours post-dose) after dosing of an extended-release formulation under fed and fasting conditions

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

  8. Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel(Cmax)

    Relative bioavailability (Frel\[Cmax\]) by assessement of the ratio of AUC (Area under the plasma concentration-time curve from time zero to 24 hours post-dose) after dosing of an extended-release formulation under fed and fasting conditions

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day

Secondary outcomes

  1. Safety and tolerabilty of AZD9977 by assessment of the number of adverse events and the number of subjects with adverse events

    To assess the safety and tolerability of single doses of AZD9977

    Time frame: From screening to post-study visit, up to 10 weeks

  2. Safety and tolerabilty of AZD9977 by assessment of cardiac telemetry

    To assess the safety and tolerability of single doses of AZD9977

    Time frame: On Day -1 and pre-dose until 24 hours post dose on Day 1

  3. Safety and tolerabilty of AZD9977 by assessment of blood pressure

    To assess the safety and tolerability of single doses of AZD9977

    Time frame: From screening to post-study visit, up to 10 weeks

  4. Safety and tolerabilty of AZD9977 by assessment of pulse

    To assess the safety and tolerability of single doses of AZD9977

    Time frame: From screening to post-study visit, up to 10 weeks

  5. Safety and tolerability of AZD9977 by assessment of electrocardiogram

    To assess the safety and tolerability of single doses of AZD9977

    Time frame: From screening to post-study visit, up to 10 weeks

  6. Safety and tolerability of AZD9977 by assessment of physical examination

    This is a composite of the general appearance, skin, cardiovascular, respiratory, abdomen, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.

    Time frame: From screening to post-study visit, up to 10 weeks

  7. Safety and tolerability of AZD9977 by assessment of safety laboratory tests

    This is a composite of clinical chemistry, hematology and urinalysis

    Time frame: From screening to post-study visit, up to 10 weeks

07

Study locations

1 site
  • Research Site
    Harrow, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2015
First posted
Sep 25, 2015
Start
Nov 2015
Primary completionEst.
Jan 2016
CompletionEst.
Jan 2016
Last update
Jan 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02560363
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
Nov 2015
Primary completion
Jan 2016 (estimated)
Completion
Jan 2016 (estimated)
Last update
Jan 11, 2016

Study contacts

Muna Albayaty, MBChB, MSc, MFPM
principal investigator · Parexel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9977

Start the discussion